A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis

This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be randomized (1:1) to: 1. discontinue antifungal treatment based on negative (\<80 pg/ml) result of 1,3 beta-d-glucan performed on day 0,3,6 and 10 2. continue antifungal treatment according with attending physician's decision.